H
IGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) has resulted in a dramatic decrease in AIDS-related morbidity and mortality in developed countries. However, the emergence of HIV-1 drug resistance is a major concern for HAART efficacy. 1 Moreover, HIV-1 drug-resistant variants can be readily transmitted, which is a factor in the spread of drug resistance.
HAART regimens have been adopted by the AIDS National Program in Venezuela since 1999. At present, approximately 10,000 adults are receiving treatment in Venezuela, 2 which represents 80% of adults in need of therapy according to the program guidelines. Therefore the present study monitors the prevalence of genotypic drug resistance and HIV-1 variability among asymptomatic-naive patients recruited at an outpatient network in Caracas. Surveillance of HIV-1 antiretroviral resistant mutations has been consistently based on genotyping from plasma RNA since this virus source is supposed to represent the currently circulating virus more accurately than proviral DNA. Nevertheless, the high correspondence among these compartments within treated patients has been shown. 3 And more recently, peripheral blood mononuclear cells have been documented as a source of archival proviral DNA and a reliable pre-Sequence edition was performed manually with the BioEdit software (Sequence Alignment Editor, version 5.0.9). Additionally, for genotypic interpretation and subtyping of isolates, edited sequences were submitted to the HIV resistance mutation database of Stanford University. 8 Sequences alignments were performed with Clustal W 1.7. 9 Phylogenetic trees were constructed with the neighbor-joining method and the reliability of the branching orders was determined by 1000 times bootstrap.
Twenty HIV-1-infected naive outpatients (women ϭ 3; men ϭ 17) coming from Caracas and the central area of the country were studied. The average CD4 ϩ count was 772 Ϯ 388 cells/mm 3 and the time since first positive ELISA was 2 Ϯ 2.5 years.
All isolates succeeded in the amplification the of env, gag, and RT regions. In the Pr region 3 of 20 isolates (15%) failed all attempts of amplification.
According to HMA results (not shown) and phylogenetic trees ( Fig. 1) , all viruses were shown to cluster with HIV-1 subtype B. However, high bootstrap values were observed for Ven-N24 and Ven-N6 with CRF07_BC reference sequences in the protease tree as well as for Ven-N10 with CRF03_AB reference sequences in the reverse transcriptase tree. Therefore this set of sequences was also submitted to the NIH-NCBI genotyping tool, 10 which confirmed subtype B in the three cases throughout their entire length. Indeed, subtype B has been consistently reported to be the principal HIV-1 strain circulating in Venezuela. [11] [12] [13] [14] Both Ven-N10 and N24 sequences correspond to viral strains of unrelated patients. The higher divergence of sequences from patients Ven-N10 and Ven-N24 could be due to a longer time of infection (ϳ9 years since the first positive serology) as compared to other patients diagnosed less than 3 years ago and with viral loads above 7000 copies/ml. In other 
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words, we could be looking at viruses representing different chronological moments of the local epidemic.
High bootstrap values (100%) among sequences Ven-N1 and Ven-N5 were verified in both trees and therefore confirmed a related source of rural infection within this couple.
Drug resistance mutations were identified only in RT: one nucleoside RT inhibitor mutation (K219Q) belonging to the mutations selected by the thymidine analogs, and one nonnucleoside RT inhibitor mutation (V108I) in two different patients. The global prevalence of drug-resistant viruses was thus 10% (2 of 20 patients). Additionally, atypical RT mutation Y188F was present.
The 10% prevalence of resistant viruses represents more than 3-fold the proportion previously found by Delgado et al. in 2001 among Venezuelan naive patients. 11 Mutations Y188F and K219R were also found in RT sequences from a naïve patient from Venezuela harboring a recombinant virus Cgag/Brt/Cenv reported by our group. 14 Together these findings suggest transmission of HIV-1 resistance to RT inhibitors in the local epidemic. Given the small number of patients included in our study, we must, however, be cautious in evaluating any dynamic trend concerning this transmission.
Overall, when comparing the frequency of mutations and polymorphisms per codon position at the RT vs. Pr region (Table 1) , we find that the frequency of mutations is clearly higher in the protease region, as already described. 15 A rare polymorphism, I62T (Table 1) was found as a single mutation in isolate 10. Therefore we sequenced the same time point RNA and found two other nucleotide substitutions (L19I and K45R) but not I62T. Polymorphism I62T was first reported in 2001 in a naive patient from Venezuela. 11 Additionally, rare mutations V77T to PIs and F227I to RTIs were identified in two different patients (Table 1) . Both mutations have been previously reported among patients receiving antiretroviral therapy (ART) and harboring either subtype B infections in the case of V77T 16, 17 or CRF02-AG infection for F2271 carriers. 18, 19 The V77T mutation is an uncommon substitution, particularly among naive patients. When sequencing RNA quasispecies at the same time point, V77T was found again, emphasizing the stability of this mutation across the different viral compartments at a set point.
This study shows a high rate of RTIs in an HIV-infected sample from Venezuela. It also highlights the role of mutations I62T and V77T as putative molecular markers of the subtype B local epidemic. Finally, it shows how proviral DNA can be used as a reliable tool to follow trends in the transmission of resistant mutations. 
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